Zheng Quan Shi Bao Wang·2025-07-01 10:19Core Viewpoint - The cell immunotherapy concept has seen a significant increase of 3.12%, ranking as the second highest in concept sector gains, with notable inflows of capital into 29 stocks within this sector [2][3]. Group 1: Market Performance - As of July 1, the cell immunotherapy concept experienced a 3.12% increase, with 45 stocks rising, including Yangpu Medical at a 20% limit up, and others like Saily Medical, Yuekang Pharmaceutical, Shutaishen, and Rongchang Bio showing gains of 15.55%, 15.34%, and 13.04% respectively [2][3]. - The leading decliners in this sector included *ST Biology, He’s Eye Hospital, and ST Zhongzhu, which fell by 1.36%, 0.63%, and 0.60% respectively [2]. Group 2: Capital Inflows - The cell immunotherapy sector attracted a net inflow of 472 million yuan, with 29 stocks receiving capital inflows, and 6 stocks seeing inflows exceeding 50 million yuan [3][4]. - Saily Medical led the net inflow with 177 million yuan, followed by Huahai Pharmaceutical, Betta Pharmaceutical, and Yangpu Medical with net inflows of 135 million yuan, 81.83 million yuan, and 75.87 million yuan respectively [3][4]. Group 3: Capital Flow Ratios - The top stocks by net inflow ratio included Yangpu Medical at 36.23%, Saily Medical at 19.83%, and Huahai Pharmaceutical at 14.87% [4]. - The detailed capital flow for key stocks showed Saily Medical with a 10% increase and a turnover rate of 29.87%, while Yangpu Medical had a 19.94% increase with a turnover rate of 9.99% [4][5].